Abstract
Sphingosine 1-phosphate (S1P) receptor modulators possess a unique mechanism of action as disease-modifying therapy for multiple sclerosis (MS). Subtype 1 S1P receptors are expressed on the surfaces of lymphocytes and are important in regulating egression from lymph nodes. The S1P receptor modulators indirectly antagonize the receptor’s function and sequester lymphocytes in lymph nodes. Fingolimod was the first S1P agent approved in the USA in 2010 for relapsing MS after two phase III trials (FREEDOMS and TRANSFORMS) demonstrated potent efficacy, and good safety and tolerability. Post-marketing experience, as well as a third phase III trial (FREEDOMS II), also showed favorable results. More selective S1P receptor agents—ponesimod (ACT128800), siponimod (BAF312), ozanimod (RPC1063), ceralifimod (ONO-4641), GSK2018682, and MT-1303—are still in relatively early stages of development, but phase I and II trials showed promising efficacy and safety. However, these observations have yet to be reproduced in phase III clinical trials.
References
Cohen JA, Chun J. Mechanisms of fingolimod’s efficacy and adverse effects in multiple sclerosis. Ann Neurol. 2011;69(5):759–77.
Chiba K, Adachi K. Sphingosine 1-phosphate receptor 1 as a useful target for treatment of multiple sclerosis. Pharmaceuticals (Basel). 2012;5(5):514–28.
Chun J, Hartung HP. Mechanism of action of oral fingolimod (FTY720) in multiple sclerosis. Clin Neuropharmacol. 2010;33(2):91–101.
Mehling M, Johnson TA, Antel J, Kappos L, Bar-Or A. Clinical immunology of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in multiple sclerosis. Neurology. 2011;76(8 Suppl 3):S20–7.
Kappos L, Radue EW, O’Connor P, Polman C, Hohlfeld R, Calabresi P, et al. A placebo-controlled trial of oral fingolimod in relapsing multiple sclerosis. N Engl J Med. 2010;362(5):387–401.
Brinkmann V, Davis MD, Heise CE, Albert R, Cottens S, Hof R, et al. The immune modulator FTY720 targets sphingosine 1-phosphate receptors. J Biol Chem. 2002;277(24):21453–7.
Paugh SW, Payne SG, Barbour SE, Milstien S, Spiegel S. The immunosuppressant FTY720 is phosphorylated by sphingosine kinase type 2. FEBS Lett. 2003;554(1–2):189–93.
Gilenya [prescribing information]. East Hanover, NJ: Novartis Pharmaceuticals Corp; 2015.
Calabresi PA, Radue EW, Goodin D, Jeffery D, Rammohan KW, Reder AT, et al. Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Neurol. 2014;13(6):545–56.
Cohen JA, Barkhof F, Comi G, Hartung HP, Khatri BO, Montalban X, et al. Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. N Engl J Med. 2010;362(5):402–15.
DiMarco JP, O’Connor P, Cohen JA, Francis G, Collins W, Zhang-Auberson L, et al. First-dose effect of fingolimod: pooled safety data from two phase-3 studies (TRANSFORMS and FREEDOMS). Mult Scler. 2010;16(10 suppl):S290.
Camm J, Hla T, Bakshi R, Brinkmann V. Cardiac and vascular effects of fingolimod: mechanistic basis and clinical implications. Am Heart J. 2014;168(5):632–44.
Forrest M, Sun S-Y, Hajdu R, Bergstrom J, Card D, Doherty G, et al. Immune cell regulation and cardiovascular effects of sphingosine 1-phosphate receptor agonists in rodents are mediated via distinct receptor subtypes. J Pharmacol Exp Ther. 2004;309(2):758–68.
Sanna MG, Liao J, Jo E, Alfonso C, Ahn MY, Peterson MS, et al. Sphingosine 1-phosphate (S1P) receptor subtypes S1P1 and S1P3, respectively, regulate lymphocyte recirculation and heart rate. J Biol Chem. 2004;279(14):13839–48.
Gergely P, Nuesslein-Hildesheim B, Guerini D, Brinkmann V, Traebert M, Bruns C, et al. The selective sphingosine 1-phosphate receptor modulator BAF312 redirects lymphocyte distribution and has species-specific effects on heart rate. Br J Pharmacol. 2012;167(5):1035–47. doi:10.1111/j.1476-5381.2012.02061.x.
Collins W, Cohen J, O’Connor P, de Vera A, Zhang-Auberson L, Jin FJ, et al. Long-term safety of oral fingolimod (FTY720) in relapsing multiple sclerosis: integrated analyses of phase 2 and 3 studies. Mult Scler. 2010;16(10 suppl):S295.
Zarbin MA, Jampol LM, Jager RD, Reder AT, Francis G, Collins W, et al. Ophthalmic evaluations in clinical studies of fingolimod (FTY720) in multiple sclerosis. Ophthalmology. 2013;120(7):1432–9.
Arvin AM, Wolinsky JS, Kappos L, Morris MI, Reder AT, Tornatore C, et al. Varicella-zoster virus infections in patients treated with fingolimod: risk assessment and consensus recommendations for management. JAMA Neurol. 2015;72(1):31–9. doi:10.1001/jamaneurol.2014.3065.
Pfender N, Jelcic I, Linnebank M, Schwarz U, Martin R. Reactivation of herpesvirus under fingolimod: A case of severe herpes simplex encephalitis. Neurology. 2015;84(23):2377–8. doi:10.1212/wnl.0000000000001659.
GILENYA® (fingolimod). Prescribing information. Basel: Novartis Pharmaceuticals; 2014.
Karlsson G, Francis G, Koren G, Heining P, Zhang X, Cohen JA, et al. Pregnancy outcomes in the clinical development program of fingolimod in multiple sclerosis. Neurology. 2014;82(8):674–80. doi:10.1212/wnl.0000000000000137.
Putzki N, Clifford DB, Bischof D, Moore A, Weinshenker BG, Freedman MS. Characteristics of PML cases in multiple sclerosis patients switching to fingolimod from natalizumab (FC3.1). Presented at the Joint ACTRIMS-ECTRIMS Meeting, October 2014.
Novartis Pharmaceuticals. Gilenya Safety Update. 2015. https://www.novartis.com/news/statements/gilenya-safety-update. Accessed 15 July 2015.
Mellen Center Approaches: use of fingolimod in MS (Gilenya, FTY720). 2010. http://my.clevelandclinic.org/ccf/media/Files/Neurological-Institute/mellen-center/13-neu-544-fingolimoid-fact-sheet.pdf. Accessed 15 July 2015.
Brown JC, Solomon SD, Bressler SB, Schachat AP, DiBernardo C, Bressler NM. Detection of diabetic foveal edema: contact lens biomicroscopy compared with optical coherence tomography. Arch Ophthalmol. 2004;122(3):330–5.
Kappos L, Radue E-W, O’Connor P, Polman C, Hohlfeld R, Calabresi P et al. Long-term efficacy and safety of fingolimod (fty720) in relapsing-remitting multiple sclerosis (rrms): results from the extension of the phase III FREEDOMS study (S41.004). Neurology. 2012;78 (Meeting Abstracts 1):S41.004.
Kappos L, O’Connor P, Radue EW, Polman C, Hohlfeld R, Selmaj K, et al. Long-term effects of fingolimod in multiple sclerosis: the randomized FREEDOMS extension trial. Neurology. 2015;20(10):1462.
Cohen JA, Arnold DL, Comi G, Bar-Or A, Gujrathi S, Hartung JP, et al. Phase 2 results of the RADIANCE trial: a randomized, double-blind, placebo-controlled trial of oral RPC1063 in relapsing multiple sclerosis (LB1.1). Mult Scler. 2014;20(1 suppl):497.
Hersh CM, Hara-Cleaver C, Rudick RA, Cohen JA, Bermel RA, Ontaneda D. Experience with fingolimod in clinical practice. Int J Neurosci. 2014;29:29.
Kerbrat A, Le Page E, Leray E, Anani T, Coustans M, Desormeaux C, et al. Natalizumab and drug holiday in clinical practice: an observational study in very active relapsing remitting multiple sclerosis patients. J Neurol Sci. 2011;308(1–2):98–102.
Miravalle A, Jensen R, Kinkel RP. Immune reconstitution inflammatory syndrome in patients with multiple sclerosis following cessation of natalizumab therapy. Arch Neurol. 2011;68(2):186–91.
Cohen M, Maillart E, Tourbah A, De Seze J, Vukusic S, Brassat D, et al. Switching from natalizumab to fingolimod in multiple sclerosis: a French prospective study. JAMA Neurol. 2014;71(4):436–41.
Jokubaitis VG, Li V, Kalincik T, Izquierdo G, Hodgkinson S, Alroughani R, et al. Fingolimod after natalizumab and the risk of short-term relapse. Neurology. 2014;82(14):1204–11.
Kappos L, Radue E-W, Comi G, Montalban X, Butzkueven H, Wiendl H, et al. Oral presentation 167: Disease control and safety in relapsing remitting multiple sclerosis (RRMS) patients switching from natalizumab to fingolimod: a 32-week, rater- and patient-blind, randomized, parallel-group study (TOFINGO). Mult Scler. 2013;19(11 suppl):50.
Bianco A, Patanella AK, Nociti V, Marti A, Frisullo G, Plantone D, et al. Second-line therapy with fingolimod for relapsing-remitting multiple sclerosis in clinical practice: the effect of previous exposure to natalizumab. Eur Neurol. 2015;73(1–2):57–65.
Comi G, Gold R, Dahlke F, Sinha A, von Rosenstiel P, Tomic D, et al. Relapses in patients treated with fingolimod after previous exposure to natalizumab. Mult Scler. 2015;21(6):786–90.
Miller D, Cree B, Dalton C, Freedman M, Hartung H, Kappos L et al. Study design and baseline characteristics of the INFORMS Study: Fingolimod in patients with primary progressive multiple sclerosis (P07.116). Neurology. 2013;80(Meeting Abstracts 1):P07.116.
Lublin F, Miller D, Freedman M, Cree B, Wolinsky J, Weiner H et al. Oral fingolimod versus placebo in patients with primary progressive multiple sclerosis (PPMS): results of the INFORMS phase III trial (abstract S56.005). Presented at the Annual Meeting of the American Academy of Neurology, May 2015.
Olsson T, Boster A, Fernandez O, Freedman MS, Pozzilli C, Bach D, et al. Oral ponesimod in relapsing-remitting multiple sclerosis: a randomised phase II trial. J Neurol Neurosurg Psychiatry. 2014;85(11):1198–208.
Selmaj K, Li DK, Hartung HP, Hemmer B, Kappos L, Freedman MS, et al. Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): an adaptive, dose-ranging, randomised, phase 2 study. Lancet Neurol. 2013;12(8):756–67.
Olson A, Hartung J, Timony G, Peach R, Boehm M, Rosen H et al. Safety and tolerability of orally administered RPC1063, a novel S1P1 receptor modulator, in healthy adult volunteers, results of a phase 1 study (P01.178). Neurology. 2013;80(Meeting Abstracts 1):P01.178.
Bar-Or A, Zipp F, Krzysztof S, Due B, Vollmer T. Effect of the sphingosine 1-phosphate receptor agonist ONO-4641 on circulating lymphocytes in patients with relapsing-remitting multiple sclerosis: results from the phase 2 DreaMS Trial (P05.153). Neurology. 2013;80(Meeting Abstracts 1):P05.153.
Bar-Or A, Zipp F, Scaramozza M, Vollmer T, Due B, Thangavelu K et al. Effect of ceralifimod (ONO-4641), a sphingosine-1-phosphate receptor-1 and -5 agonist, on magnetic resonance imaging outcomes in patients with multiple sclerosis: interim results from the extension of the DreaMS Study (P3.161). Neurology. 2014;82(10 Supplement):P3.161.
Vollmer T, Selmaj K, Bar-Or A, Zipp F. A, double-blind, placebo-controlled, phase 2, 26-week dreams trial of a selective s1p receptor agonist ONO-4641 in patients with relapsing–remitting multiple sclerosis (S31.005). Neurology. 2012;79(11):e90.
Xu J, Gray F, Henderson A, Hicks K, Yang J, Thompson P, et al. Safety, pharmacokinetics, pharmacodynamics, and bioavailability of GSK2018682, a sphingosine-1-phosphate receptor modulator, in healthy volunteers. Clin Pharmacol Drug Dev. 2014;3(3):170–8.
Krause A, Brossard P, D’Ambrosio D, Dingemanse J. Population pharmacokinetics and pharmacodynamics of ponesimod, a selective S1P1 receptor modulator. J Pharmacokin Pharmacodyn. 2014;41(3):261–78.
Kappos L, Antel J, Comi G, Montalban X, O’Connor P, Polman CH, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006;355(11):1124–40.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflicts of interest
AM Subei has nothing to disclose. JA Cohen is an editor of Multiple Sclerosis Journal—Experimental, Translational and Clinical and reports personal fees from EMD Serono, Genentech, Genzyme, Novartis, Receptos, Teva, and Vaccinex for consulting.
Funding
AM Subei is supported by Clinician Care Fellowship Award CF 00104N-1 from the National Multiple Sclerosis Society, which funded the time allocated to developing the manuscript. Otherwise no direct funding was received.
Rights and permissions
About this article
Cite this article
Subei, A.M., Cohen, J.A. Sphingosine 1-Phosphate Receptor Modulators in Multiple Sclerosis. CNS Drugs 29, 565–575 (2015). https://doi.org/10.1007/s40263-015-0261-z
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40263-015-0261-z